keyword
MENU ▼
Read by QxMD icon Read
search

Non Clear Cell RCC

keyword
https://www.readbyqxmd.com/read/29767327/follow-up-after-curative-treatment-of-localised-renal-cell-carcinoma
#1
REVIEW
Saeed Dabestani, Lorenzo Marconi, Teele Kuusk, Axel Bex
PURPOSE: Patients with localised renal cell carcinoma (RCC) receiving curative surgery, either radical or partial nephrectomy, have been shown in contemporary studies to develop recurrence within 5 years in 20-30% of case. Therefore, post-operative follow-up (FU) imaging plays a crucial role in detecting recurrent or metastatic disease. A number of prognostic scores have been developed to predict risk of recurrence. This review summarises the current knowledge on established FU protocols and their limitations...
May 16, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29762256/computed-tomography-perfusion-measurements-in-renal-lesions-obtained-by-bayesian-estimation-advanced-singular-value-decomposition-deconvolution-maximum-slope-and-patlak-models-intermodel-agreement-and-diagnostic-accuracy-of-tumor-classification
#2
Dominik Deniffel, Timothé Boutelier, Aissam Labani, Mickael Ohana, Daniela Pfeiffer, Catherine Roy
OBJECTIVES: The aims of this study were to evaluate the agreement of computed tomography (CT)-perfusion parameter values of the normal renal cortex and various renal tumors, which were obtained by different mathematical models, and to evaluate their diagnostic accuracy. MATERIALS AND METHODS: Perfusion imaging was performed prospectively in 35 patients to analyze 144 regions of interest of the normal renal cortex and 144 regions of interest of renal tumors, including 21 clear-cell renal cell carcinomas (RCC), 6 papillary RCCs, 5 oncocytomas, 1 chromophobe RCC, 1 angiomyolipoma with minimal fat, and 1 tubulocystic RCC...
May 14, 2018: Investigative Radiology
https://www.readbyqxmd.com/read/29748390/the-clinical-activity-of-pd-1-pd-l1-inhibitors-in-metastatic-non-clear-cell-renal-cell-carcinoma
#3
Rana R McKay, Dominick Bossé, Wanling Xie, Stephanie A M Wankowicz, Abdallah Flaifel, Raphael Brandao, Aly-Khan Lalani, Dylan J Martini, Xiao X Wei, David A Braun, Eliezer M Van Allen, Daniel Castellano, Guillermo de Velasco, J Connor Wells, Daniel Y C Heng, Andre P Fay, Fabio A Schutz, JoAnn Hsu, Sumanta Kumar Pal, Jae-Lyun Lee, James Hsieh, Lauren C Harshman, Sabina Signoretti, Robert J Motzer, Darren R Feldman, Toni K Choueiri
Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non-clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation is limited. In this multicenter analysis, we explored the efficacy of PD-1/PD-L1 inhibitors in patients with nccRCC or sarcomatoid/rhabdoid differentiation. Baseline and follow-up demographic, clinical, treatment, and radiographic data were collected...
May 10, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29693713/low-nr3c2-levels-correlate-with-aggressive-features-and-poor-prognosis-in-non-distant-metastatic-clear-cell-renal-cell-carcinoma
#4
Zhijian Zhao, Mengping Zhang, Xiaolu Duan, Tuo Deng, Huijuan Qiu, Guohua Zeng
NR3C2 has previously been described as a tumor suppressor gene in several cancers; however the prognostic significance and biological function of NR3C2 in patients with non-metastatic clear cell renal cell carcinoma (ccRCC) remain largely unclear. The prognostic value of NR3C2 expression was evaluated using data from The Cancer Genome Atlas (TCGA) and 181 patients with non-metastatic ccRCC undergoing nephrectomy in our center. Predictive nomograms were generated and identified independent prognosticators to assess ccRCC patient overall survival (OS) and progression free survival (PFS) at 1, 5, and 8 years...
April 25, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29691619/quantitative-multiparametric-mr-analysis-of-small-renal-lesions-correlation-with-surgical-pathology
#5
Motoyo Yano, Kathryn J Fowler, Santip Srisuwan, Amber Salter, Cary L Siegel
PURPOSE: The purpose of the study is to evaluate the utility of apparent diffusion coefficient (ADC), chemical shift signal intensity index (SII), and contrast enhancement in distinguishing between benign lesions and renal cell carcinoma (RCC) and between subtypes of renal lesions. METHODS: This retrospective study included 98 renal lesions (≤ 3 cm) on MRI with correlative surgical pathology. Scanner field strength, lesion location, and size were recorded. Two readers blinded to surgical pathology independently measured ADC ratio (ADC lesion/ADC non-lesion kidney), SII, and absolute/relative enhancement in the corticomedullary and nephrographic phases of contrast...
April 24, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/29684960/-two-cases-of-metastatic-and-recurrent-non-clear-cell-renal-cell-carcinoma-re-diagnosed-as-renal-mucinous-tubular-and-spindle-cell-carcinoma-during-long-term-follow-up
#6
Masashi Kubota, Toshinari Yamasaki, Yuki Teramoto, Katsuhiro Ito, Hideaki Takada, Toshihiro Magaribuchi, Atsuro Sawada, Shusuke Akamatsu, Hiromitsu Negoro, Ryoichi Saito, Takashi Kobayashi, Naoki Terada, Takahiro Inoue, Tomomi Kamba, Osamu Ogawa
Renal mucinous tubular and spindle cell carcinoma (MTSCC) is a rare, low-grade renal epithelial neoplasm. MTSCC has a lower malignant potential and shows relatively good prognosis, but can be difficult to distinguish from other renal cell carcinoma (RCC) subtypes. Here, we report two cases of metastatic and recurrent renal MTSCC diagnosed after long-term follow-up. Case 1 was a 79-year-old man with a history of macroscopic hematuria in whom a right kidney mass was detected and diagnosed as RCC (cT3bN0M0). After a radical nephrectomy, microscopic findings showed that the tumor consisted of spindle cells arranged in tubular patterns embedded in sarcomatoid tissues ; we diagnosed it as unclassified RCC with sarcomatoid differentiations (pT3aN0M0)...
March 2018: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29680948/hereditary-renal-cell-carcinoma-syndromes-diagnosis-surveillance-and-management
#7
REVIEW
Eamonn R Maher
PURPOSE: Genetic factors have been implicated in the pathogenesis of renal cell carcinoma (RCC), with around 3% of cases having a family history. A greater knowledge of the genetics of inherited RCC has the potential to translate into novel therapeutic targets for sporadic RCC. METHODS: A literature review was performed summarising the current knowledge on hereditary RCC diagnosis, surveillance and management. RESULTS: Familial RCC is usually inherited in an autosomal dominant manner, although inherited RCC may present without a relevant family history...
April 21, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29669553/significant-response-to-nivolumab-for-metastatic-chromophobe-renal-cell-carcinoma-with-sarcomatoid-differentiation-a-case-report
#8
Go Noguchi, Sohgo Tsutsumi, Masato Yasui, Shinji Ohtake, Susumu Umemoto, Noboru Nakaigawa, Masahiro Yao, Takeshi Kishida
BACKGROUND: The treatment of advanced or metastatic renal cell carcinoma (RCC) has drastically changed since the approval of immune checkpoint therapy. Nivolumab is a treatment option for patients with metastatic RCC, previously treated with targeted antiangiogenic therapy. The efficacy of nivolumab for patients with RCC was established by the Checkmate 025 clinical trial. Chromophobe RCC (CRCC) represents around 5% of RCC cases, but non-clear cell RCC (non-ccRCC) subtypes were excluded from the Checkmate 025 clinical trial...
April 18, 2018: BMC Urology
https://www.readbyqxmd.com/read/29658093/metabolomic-study-of-human-tissue-and-urine-in-clear-cell-renal-carcinoma-by-lc-hrms-and-pls-da
#9
Joanna Nizioł, Vincent Bonifay, Krzysztof Ossoliński, Tadeusz Ossoliński, Anna Ossolińska, Jan Sunner, Iwona Beech, Adrian Arendowski, Tomasz Ruman
Renal cell carcinoma (RCC) is the most prevalent and lethal malignancy of the kidney. Despite all the efforts made, no tissue biomarker is currently used in the clinical management of patients with kidney cancer. A search for possible biomarkers in urine for clear cell renal cell carcinoma (ccRCC) has been conducted. Non-targeted metabolomic analyses were performed on paired samples of surgically removed renal cancer and normal tissue, as well as on urine samples. Extracts were analyzed by liquid chromatography/high-resolution mass spectrometry (LC-HRMS)...
April 16, 2018: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/29629865/clinicopathological-significance-of-galectin-1-expression-and-percentage-of-galectin-1-expressing-t-cells-in-clear-cell-renal-cell-carcinoma
#10
Yajuan Su, Wentao Wang, Yongpeng Xu, Wei Liangjun, Yanjie Wang, Changfu Li, Lichen Teng
INTRODUCTION: This study investigates clinical significance of galectin-1 expression in carcinoma tissues, plasma, and lymphocytes of patients with clear-cell renal cell carcinoma (RCC). METHODS: Galectin-1 expression was investigated, using immunohistochemistry, in 91 clear-cell RCC tissue sections, five angioleiolipomas tissue sections, and three oncocytomas tissue sections. As controls, normal tissue sections adjacent to each tumour and six benign renal tumour sections were examined...
March 25, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29550805/renal-cell-carcinoma-with-monosomy-8-a-case-series-and-review-of-the-literature
#11
Justin Rueckert, Katherine Devitt, Juli-Anne Gardner
Renal cell carcinoma (RCC) is a malignancy commonly encountered by both clinicians and pathologists. Different RCC subtypes are classified based on histologic features, immunohistochemistry profiles, and cytogenetic abnormalities. Accurate diagnosis of subtypes is important as it has prognostic and therapeutic implications. The most common RCC subtype is clear cell renal cell carcinoma (CCRCC); the most frequent genetic abnormalities associated with CCRCC are a deletion of the short arm of chromosome 3 involving 3p21 and mutations involving the Von Hippel-Lindau (VHL) gene...
2018: Journal of the Association of Genetic Technologists
https://www.readbyqxmd.com/read/29511402/metastatic-renal-cell-carcinoma-as-solitary-subcentimeter-polypoid-gastric-mucosal-lesions-clinicopathologic-analysis-of-five-cases
#12
Amanda Hemmerich, Mohanad Shaar, Rebecca Burbridge, Cynthia D Guy, Shannon J McCall, Diana M Cardona, Xuchen Zhang, Jinping Lai, Xuefeng Zhang
Background: The stomach is an uncommon site for metastatic carcinoma. Approximately 6% of renal cell carcinomas (RCCs) may metastasize to the stomach. The majority of the reported metastatic RCCs in the stomach presented as large masses or ulcers greater than a centimeter in size. It is very rare to encounter metastatic RCC as a solitary small polypoid gastric mucosal lesion. Methods: In this study, we collected surgical pathology cases of gastric metastasis from RCC that measured 1...
February 2018: Gastroenterology Research
https://www.readbyqxmd.com/read/29498788/high-ido-1-expression-in-tumor-endothelial-cells-is-associated-with-response-to-immunotherapy-in-metastatic-renal-cell-carcinoma
#13
Andreas Seeber, Gerald Klinglmair, Josef Fritz, Fabian Steinkohl, Kai-Christian Zimmer, Friedrich Aigner, Wolfgang Horninger, Günther Gastl, Bettina Zelger, Andrea Brunner, Renate Pichler
Nivolumab belongs to the standard therapy in the second-line setting of metastatic renal cell carcinoma (mRCC). Although deep and long-lasting responses are seen in some patients, the majority of patients will further progress. PD-L1 is still under critical evaluation as a predictive biomarker. Thus, more accurate biomarkers are clearly warranted. Here, we investigated for the first time the predictive role of IDO-1, a negative immune-regulatory molecule, on clear cell RCC tissues of 15 patients undergoing nivolumab therapy...
March 2, 2018: Cancer Science
https://www.readbyqxmd.com/read/29464464/pazopanib-related-tumor-lysis-syndrome-in-metastatic-clear-cell-renal-cell-carcinoma-a-case-report
#14
Michael W van Kalleveen, Maudy Walraven, Mathijs P Hendriks
Introduction Tumor lysis syndrome (TLS) is a life-threatening emergency caused by rapid cell death as a result of anti-tumor therapy. In the era of targeted therapy it has increasingly been observed in solid malignancies such as hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Case We describe the case of a 58-year old man with the medical history of a memorial sloan kettering cancer centre (MSKCC) poor prognosis metastasized clear cell renal cell carcinoma (mRCC) who developed TLS within six days after initiating therapy with the tyrosine kinase inhibitor (TKI) pazopanib...
February 20, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29452772/metabolic-and-lipidomic-reprogramming-in-renal-cell-carcinoma-subtypes-reflects-regions-of-tumor-origin
#15
Elke Schaeffeler, Florian Büttner, Anna Reustle, Verena Klumpp, Stefan Winter, Steffen Rausch, Pascale Fisel, Jörg Hennenlotter, Stephan Kruck, Arnulf Stenzl, Judith Wahrheit, Denise Sonntag, Marcus Scharpf, Falko Fend, Abbas Agaimy, Arndt Hartmann, Jens Bedke, Matthias Schwab
BACKGROUND: Renal cell carcinoma (RCC) consists of prognostic distinct subtypes derived from different cells of origin (eg, clear cell RCC [ccRCC], papillary RCC [papRCC], and chromophobe RCC [chRCC]). ccRCC is characterized by lipid accumulation and metabolic alterations, whereas data on metabolic alterations in non-ccRCC are limited. OBJECTIVE: We assessed metabolic alterations and the lipid composition of RCC subtypes and ccRCC-derived metastases. Moreover, we elucidated the potential of metabolites/lipids for subtype classification and identification of therapeutic targets...
February 13, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29414519/fat-status-detection-and-histotypes-differentiation-in-solid-renal-masses-using-dixon-technique
#16
Jun Sun, Zhaoyu Xing, Jie Chen, Tingting Zha, Yunjie Cao, Dachuan Zhang, Dexing Zeng, Wei Xing
PURPOSE: To detect fat status and differentiate histotypes of renal masses by using Dixon technique. MATERIALS AND METHODS: This study included 134 solid renal masses. Signal intensity index (SII) and fat fraction (FF) in different histotypes were compared. RESULTS: Only angiomyolipoma (AML), clear cell renal cell carcinoma (RCC), and papillary RCC were confirmed to contain fat. The FF of 16.8% can effectively differentiate AML from clear cell RCC, so did the SII of 9...
January 30, 2018: Clinical Imaging
https://www.readbyqxmd.com/read/29410711/serum-mir-122-5p-and-mir-206-expression-non-invasive-prognostic-biomarkers-for-renal-cell-carcinoma
#17
Frauke G Heinemann, Yuri Tolkach, Mario Deng, Doris Schmidt, Sven Perner, Glen Kristiansen, Stefan C Müller, Jörg Ellinger
Background: MicroRNAs (miRNA) play a relevant role in carcinogenesis, cancer progression, invasion, and metastasis. Thus, they can serve as diagnostic/prognostic biomarkers. The knowledge on circulating miRNAs for clear cell renal cell carcinomas (ccRCC) is limited. Our study was designed to identify novel biomarkers for ccRCC patients. Results: The serum small RNA expression profile was determined in 18 ccRCC and 8 patients with benign renal tumors (BRT) using small RNA sequencing...
2018: Clinical Epigenetics
https://www.readbyqxmd.com/read/29387555/a-novel-preoperative-inflammatory-marker-prognostic-score-in-patients-with-localized-and-metastatic-renal-cell-carcinoma
#18
Rishi R Sekar, Dattatraya Patil, Yoram Baum, Jeffrey Pearl, Anna Bausum, Mehmet A Bilen, Omer Kucuk, Wayne B Harris, Bradley C Carthon, Mehrdad Alemozaffar, Christopher P Filson, John G Pattaras, Peter T Nieh, Kenneth Ogan, Viraj A Master
Objective: Several inflammatory markers have been studied as potential biomarkers in renal cell carcinoma (RCC), however few reports have analyzed their prognostic value in aggregate and in non-clear cell histologies. We hypothesize that a combination of specific inflammatory markers into an RCC Inflammatory Score (RISK) could serve as a rigorous prognostic indicator of overall survival (OS) in patients with clear cell and non-clear cell RCC. Methods: Combination of preoperative C-reactive protein (CRP), albumin, erythrocyte sedimentation rate (ESR), corrected calcium, and aspartate transaminase to alanine transaminase (AST/ALT) ratio was used to develop RISK...
October 2017: Asian Journal of Urology
https://www.readbyqxmd.com/read/29382453/accuracy-of-kidney-cancer-diagnosis-and-histological-subtype-within-canadian-cancer-registry-data
#19
Jeffrey G Himmelman, Jennifer Merrimen, Kara Matheson, Chris Theriault, Lori A Wood
INTRODUCTION: Provincial/territorial cancer registries (PTCRs) are the mainstay for Canadian population-based cancer statistics. Each jurisdiction captures this data in a population-based registry, including the Nova Scotia Cancer Registry (NSCR). The goal of this study was to describe data from the NSCR regarding renal cell carcinoma (RCC) pathology subtype and method of diagnosis and compare it to the actual pathology reports to determine the accuracy of diagnosis and histological subtype assignment...
September 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29378660/clinical-activity-of-nivolumab-in-patients-with-non-clear-cell-renal-cell-carcinoma
#20
Vadim S Koshkin, Pedro C Barata, Tian Zhang, Daniel J George, Michael B Atkins, William J Kelly, Nicholas J Vogelzang, Sumanta K Pal, JoAnn Hsu, Leonard J Appleman, Moshe C Ornstein, Timothy Gilligan, Petros Grivas, Jorge A Garcia, Brian I Rini
BACKGROUND: Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were excluded from the original nivolumab trials. METHODS: Patients from 6 centers in the United States who received at least one dose of nivolumab for non-clear cell mRCC between 12/2015 and 06/2017 were identified. A retrospective analysis including patient characteristics, objective response rate according to RECIST v1...
January 29, 2018: Journal for Immunotherapy of Cancer
keyword
keyword
104989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"